mcl: fda approval of a second-generation btk inhibitor
Published 4 years ago • 57 plays • Length 4:03Download video MP4
Download video MP3
Similar videos
-
7:11
selection of a btk inhibitor in relapsed/refractory mcl
-
59:49
rebooting the btk inhibitor sequence in mcl
-
5:59
differentiating btk inhibitor mechanisms of action in mcl
-
8:38
acalabrutinib, second-generation btk inhibitor for cll
-
1:32
selecting btk inhibitors for patients with mcl
-
0:59
dr. rule on the fda approval of zanubrutinib in mcl
-
1:47
dr. leslie on the role of btk inhibitors in relapsed/refractory mcl
-
1:05
dr. fenske on the utility of next-generation btk inhibitors in mcl
-
4:16
mcl: differences in trial design between btk inhibitors
-
4:13
mcl: novel btk inhibitor combination strategies
-
5:07
btk inhibitors in mcl: aes, specificity, and interactions
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
1:29
dr. wang on the benefit of btk inhibitors in mcl
-
3:36
distinguishing features among btk inhibitors
-
1:56
dr. rule on the role of btk inhibitors in mcl
-
2:00
dr. goy discusses btk inhibitors in mcl
-
4:54
second-generation btk inhibitors in cll
-
0:55
dr. smith on safety profiles of btk inhibitors in mcl
-
3:19
fda-approved agents for the treatment of mcl